The innate immune system forms the first line of defense and plays an important role in triggering long-lasting adaptive immune responses. Our therapies are aimed at bridging and activating these two powerful arms of the human immune system.
We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat” signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
TTI-621 has shown single agent activity in patients with B- and T-cell lymphomas. We are continuing to work diligently to translate these promising clinical findings into an approval pathway and explore the activity of our decoy receptors in other tumor types, as both monotherapy and in combination with other agents.
Our lead CD47 blocker, TTI-621, is a potent, dual function molecule that is designed to inhibit CD47 on the tumor cell and simultaneously deliver an activating signal to the immune system, whereas most competitor CD47 blockers require a second drug for full activation. In addition, Trillium’s SIRPαFc decoy receptors do not bind to normal human red blood cells, thus minimizing certain undesired effects seen with other CD47 targeting agents, such as anemia.